Meta-analysis shows high response rates and durable remission for CAR-T therapy in frontline multiple myeloma, suggesting further large trials are necessary.
Key Points
To explore the effectiveness of CAR-T therapy in treating newly diagnosed multiple myeloma in a frontline setting.
Comprehensive search of relevant databases following PRISMA guidelines.
Screening and selection of studies focusing on CAR-T therapy in frontline multiple myeloma.
Conducted a meta-analysis using random-effects model to estimate outcomes.
Overall response rate was 99% with a 95% confidence interval (CI) of 0.96-1.00.
Complete response rate was 90% (95% CI: 0.82-0.96).
Minimal residual disease negativity at 6 months was 89% and at 12 months was 82%.
2% treatment-related mortality rate was observed.
Neutropenia (grade 3 or above) occurred in 65% of patients.